Most-Upgraded StocksMost-UpgradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News $735.56 +6.96 (+0.96%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$727.41▼$736.7150-Day Range$725.00▼$830.3552-Week Range$538.01▼$837.55Volume740,205 shsAverage Volume599,755 shsMarket Capitalization$80.42 billionP/E Ratio19.99Dividend YieldN/APrice Target$850.21 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside16.1% Upside$854.13 Price TargetShort InterestHealthy1.11% of Shares Sold ShortDividend StrengthN/ASustainability-1.97Upright™ Environmental ScoreNews Sentiment0.73Based on 12 Articles This WeekInsider TradingSelling Shares$10.22 M Sold Last QuarterProj. Earnings Growth4.86%From $34.76 to $36.45 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector106th out of 1,006 stocksPharmaceutical Preparations Industry40th out of 492 stocks 3.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.74, and is based on 18 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $854.13, Regeneron Pharmaceuticals has a forecasted upside of 16.1% from its current price of $735.56.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.11% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 2.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 47.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Cardiovascular system medication (C)" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -1.97. Previous Next 2.6 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Regeneron Pharmaceuticals this week, compared to 11 articles on an average week.Search InterestOnly 19 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat Follows13 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,218,737.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.25% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 4.86% in the coming year, from $34.76 to $36.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 19.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 19.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 127.65.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regeneron Pharmaceuticals (NASDAQ:REGN) StockRegeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.Read More Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesMay 5, 2023 | marketbeat.comRegeneron Beats Q1 Views, But Stock Drops On Weak Eye Med SalesRegeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.May 30, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)June 1, 2023 | UNKNOWN (Ad)Highly Profitable Restaurant Brand Expands to CanadaInvest in the Canadian Expansion with Debut: The Exclusive Franchisee with Proven Success.May 27, 2023 | americanbankingnews.comBrokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $850.91May 26, 2023 | finance.yahoo.comRegeneron (REGN) Posts Upbeat Data From Multiple Myeloma StudyMay 26, 2023 | msn.comRegeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71%May 25, 2023 | msn.comRegeneron Pharmaceuticals Unusual Options Activity For May 25May 25, 2023 | finance.yahoo.comFianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient PopulationsJune 1, 2023 | UNKNOWN (Ad)Highly Profitable Restaurant Brand Expands to CanadaInvest in the Canadian Expansion with Debut: The Exclusive Franchisee with Proven Success.May 25, 2023 | finance.yahoo.comUpdated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple MyelomaMay 25, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME GroupMay 25, 2023 | finance.yahoo.com14 Best Biotech Stocks To Buy According To Hedge FundsMay 22, 2023 | benzinga.comHere's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth TodayMay 22, 2023 | msn.comSanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, SustainedMay 22, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at StockNews.comMay 22, 2023 | reuters.comSanofi: smoker's lung drug benefit was swift and sustained in trialMay 20, 2023 | finance.yahoo.comRegeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five yearsMay 19, 2023 | msn.comRegeneron (REGN) Faces Challenges as Eylea Sales DeclineMay 19, 2023 | benzinga.comHigh School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023May 19, 2023 | finance.yahoo.comHigh School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023May 18, 2023 | finance.yahoo.comRegeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific InnovationMay 16, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference TranscriptMay 16, 2023 | msn.comRBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform RecommendationMay 16, 2023 | finance.yahoo.comRegeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?May 13, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call TranscriptMay 11, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at StockNews.comMay 11, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $935.00 at GuggenheimSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Company Calendar Last Earnings2/03/2023Today5/31/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,851Year Founded1988Price Target and Rating Average Stock Price Forecast$854.13 High Stock Price Forecast$1,050.00 Low Stock Price Forecast$625.00 Forecasted Upside/Downside+15.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$36.80 Trailing P/E Ratio19.99 Forward P/E Ratio21.16 P/E Growth2.32Net Income$4.34 billion Net Margins33.81% Pretax Margin37.64% Return on Equity20.41% Return on Assets15.79% Debt Debt-to-Equity Ratio0.11 Current Ratio5.45 Quick Ratio4.67 Sales & Book Value Annual Sales$12.17 billion Price / Sales6.61 Cash Flow$45.18 per share Price / Cash Flow16.28 Book Value$214.91 per share Price / Book3.42Miscellaneous Outstanding Shares109,330,000Free Float99,673,000Market Cap$80.42 billion OptionableOptionable Beta0.23 Social Links Key ExecutivesLeonard S. SchleiferCo-President, Chief Executive Officer & DirectorGeorge Damis YancopoulosCo-President, Director & Chief Scientific OfficerPatrice GiloolySenior VP-Quality Assurance & OperationsRobert E. LandryChief Financial Officer & Executive VP-FinanceNeil StahlExecutive VP-Research & DevelopmentKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXAlnylam PharmaceuticalsNASDAQ:ALNYZoetisNYSE:ZTSGSKNYSE:GSKTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsiders & InstitutionsWarther Private Wealth LLCBought 55 shares on 5/30/2023Ownership: 0.003%ProShare Advisors LLCBought 9,788 shares on 5/26/2023Ownership: 0.105%Toroso Investments LLCSold 2,717 shares on 5/23/2023Ownership: 0.005%3Chopt Investment Partners LLCBought 1,250 shares on 5/23/2023Ownership: 0.001%Seaport Global Advisors LLCBought 136 shares on 5/23/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions REGN Stock - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price forecast for 2023? 23 analysts have issued 1-year target prices for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $625.00 to $1,050.00. On average, they expect the company's share price to reach $854.13 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2023? Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of 2023. Since then, REGN shares have increased by 2.0% and is now trading at $735.56. View the best growth stocks for 2023 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 earnings per share for the quarter, beating analysts' consensus estimates of $8.18 by $4.38. The biopharmaceutical company earned $3.41 billion during the quarter, compared to the consensus estimate of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 33.81% and a trailing twelve-month return on equity of 20.41%. Regeneron Pharmaceuticals's quarterly revenue was down 31.1% on a year-over-year basis. During the same quarter last year, the firm earned $23.72 EPS. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust US Equity Opportunities ETF (FPX), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Simplify Health Care ETF (PINK), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA) and Invesco Dynamic Biotechnology & Genome ETF (PBE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (8.63%), BlackRock Inc. (8.61%), State Street Corp (4.48%), Dodge & Cox (2.18%), Geode Capital Management LLC (2.03%) and Price T Rowe Associates Inc. MD (1.99%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $735.56. How much money does Regeneron Pharmaceuticals make? Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.42 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $36.80 on an earnings per share basis. How many employees does Regeneron Pharmaceuticals have? The company employs 11,851 workers across the globe. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113. This page (NASDAQ:REGN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.